Ritedose Doubles Vial Packaging Capacity with New Syntegon Line to Support Ohtuvayre COPD Drug Production
Key Insights
Ritedose (search) is installing a seventh Syntegon (search) packaging line that will double its capacity to produce individually wrapped vial medications, processing up to 170 million vials annually.
The expanded capacity will support manufacturing of Verona Pharma's Ohtuvayre (search), a first-in-class PDE3 (search) and PDE4 (search) inhibitor for COPD (search) that represents the first novel inhaled mechanism of action approved in over 20 years.
This investment follows Ritedose (search)'s summer 2024 expansion of sterile Blow-Fill-Seal capabilities by 180 million units, reinforcing its position as the largest CDMO in the US specializing in sterile unit dose solutions.
The Ritedose (search) Corporation, Inc. (Ritedose) is expanding its manufacturing capabilities with the addition of a seventh Syntegon (search) packaging line at its Columbia, South Carolina facility. This strategic expansion, expected to be operational by early summer 2025, will double the company's capacity to package single, individually wrapped vial medications.
The new automated packaging system will significantly increase Ritedose (search)'s production capabilities, enabling the processing of between 160 million and 170 million vials annually. This expansion comes in response to anticipated growing demand for individually wrapped vial medications in the pharmaceutical market.
Supporting Novel COPD Treatment Production
A primary driver for this expansion is Ritedose (search)'s manufacturing partnership with Verona Pharma for Ohtuvayre (search), a breakthrough treatment for Chronic Obstructive Pulmonary Disease (search) (COPD (search)). Announced in September 2024, this collaboration positions Ritedose as Verona's manufacturing partner of choice.
Ohtuvayre (search) represents a significant advancement in COPD (search) treatment as the first inhaled product with a novel mechanism of action approved in more than two decades. The drug functions as a first-in-class dual PDE3 (search) and PDE4 (search) inhibitor, offering a new therapeutic approach for COPD patients.
"At Ritedose (search), we make significant investments to support our expanding manufacturing efforts," said Jody Chastain, Ritedose President and Chief Executive Officer. "This summer we expanded our sterile Blow-Fill-Seal (BFS) capabilities by an additional 180-million-unit dose capacity for ophthalmic and respiratory medications. These investments underscore our commitment to meeting the demands for high-quality, sterile unit dose solutions. Our seventh Syntegon (search) packaging line will greatly enhance our ability to serve Verona Pharma and future clients."
Expanding Sterile Manufacturing Capabilities
As the largest contract development manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal production, Ritedose (search) focuses on unit dose solutions for the ophthalmic and respiratory markets. The new packaging line will be operated by highly skilled professionals dedicated to maintaining Ritedose's standards for sterile manufacturing excellence.
The Syntegon (search) system is specifically designed for automated secondary packaging of pharmaceutical products, with features that maximize output while reducing waste. The technology reinforces Ritedose (search)'s commitment to patient safety and quality in pharmaceutical production.
Broader Impact on Pharmaceutical Manufacturing
Beyond supporting Ohtuvayre (search) production, the additional packaging capacity enables Ritedose (search) to meet individually wrapped vial packaging needs for other therapeutic areas, including ophthalmic medications. This expansion enhances the company's flexibility to serve diverse client requirements across multiple disease states.
The investment builds upon Ritedose (search)'s long-standing relationship with Syntegon (search) Technology, which has provided reliable packaging solutions for the company's pharmaceutical products for more than 20 years. The new system is currently undergoing Site Acceptance Testing at the Ritedose facility.
By increasing both efficiency and flexibility in its operations, Ritedose (search) is positioning itself to better serve the evolving needs of pharmaceutical companies and, ultimately, patients requiring precise, sterile unit-dose medications.